RxDoctor Payments Data

Ganesh Krishna, MD

Pulmonary Disease · Mountain View, CANPI 1407890742

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (41.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 89.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $62,038 and has fallen 82.2% since, to $11,055 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$186,602in general payments, 2019–2025

Across 292 payments — averaging $639.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$167K
  • Cook Incorporated$7K
  • Gyrus ACMI, Inc.$3K
  • Olympus America Inc.$3K
  • Covidien LP$2K
  • Pulmonx Corporation$2K
  • plus $3K from 10 others
$320,435in research payments, 2019–2025

Across 48 payments — averaging $6675.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gyrus ACMI, Inc.$294K
  • Pneumrx, Inc$10K
  • Pulmonx Corporation$9K
  • Pfizer$3K
  • Auris Health, Inc.$3K
  • Spiration, Inc.$453

What the payments were for

  • Consulting fees$16,2559%
  • Speaking & faculty fees$66,32036%
  • Travel & lodging$16,7709%
  • Food & beverage$10,1215%
  • Education$77,13541%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$186,602 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$170,125
Medicare patients
279
Services billed
1,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spiriva RespimatTiotropium Bromide28$23,622
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,700
Breo ElliptaFluticasone/Vilanterol15$9,458
Prednisone25$35

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →